Back to Authors

Snyder, Erin Dunn

0000-0001-5864-1706

Mayo Clinic

19O’Neal Comprehensive Cancer Center at UAB;

Citations 1

NCCN Guidelines Insights: B-Cell Lymphomas, Version 3.2019
Advani, Ranjana H. , Bartlett, Nancy L. , Chang, Julie , Christian, Beth , Fayad, Luis , Glenn, Martha, Hernandez‐Ilizaliturri, Francisco J. , Kaminski, Mark , Khan, Nadia , Krivacic, Susan, LaCasce, Ann S. , Nademanee, Auayporn, Rabinovitch, Rachel , Reddy, Nishitha , Roberts, Kenneth B. , Smith, Stephen D. , Swinnen, Lode J., Dwyer, Mary A., Sundar, Hema, Bartlett, Nancy L , Advani, Ranjana H , Khan, Nadia , Zelenetz, Andrew D. , Gordon, Leo I. , Abramson, Jeremy S. , Caimi, Paolo F. , Chavez, Julio C , Habermann, Thomas M. , Harris, Nancy L. , Kelsey, Chris R. , Mehta, Amitkumar , Reid, Erin G , Snyder, Erin Dunn , Vose, Julie M.

Journal of the National Comprehensive Cancer Network | June 17, 2019 | Volume: 17 | Issue: 6 | Pages: 650-661

10.6004/jnccn.2019.0029 Get It

Diffuse large B-cell lymphomas (DLBCLs) and follicular lymphoma (FL) are the most common subtypes of B-cell non-Hodgkin’s lymphomas in adults. Histologic transformation of FL to DLBCL (TFL) occurs in approximately 15% of patients and is generally associated with a poor clinical outcome. Phosphatidylinositol 3-kinase (PI3K) inhibitors have shown promising results in the treatment of relapsed/refractory FL. CAR T-cell therapy (axicabtagene ciloleucel and tisagenlecleucel) has emerged as a novel treatment option for relapsed/refractory DLBCL and TFL. These NCCN Guidelines Insights highlight important updates to the NCCN Guidelines for B-Cell Lymphomas regarding the treatment of TFL and relapsed/refractory FL and DLBCL.